Allogene Therapeutics Inc ALLO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 9:38 AM EDT
25.37quote price arrow down-0.29 (-1.13%)
Volume
12,149
52 week range
20.58 - 44.92
Loading...
  • Open25.66
  • Day High25.66
  • Day Low25.29
  • Prev Close25.66
  • 52 Week High44.92
  • 52 Week High Date10/14/20
  • 52 Week Low20.58
  • 52 Week Low Date08/12/21

Key Stats

  • Market Cap3.607B
  • Shares Out142.18M
  • 10 Day Average Volume0.74M
  • Dividend-
  • Dividend Yield-
  • Beta1.08
  • YTD % Change1.66

KEY STATS

  • Open25.66
  • Day High25.66
  • Day Low25.29
  • Prev Close25.66
  • 52 Week High44.92
  • 52 Week High Date10/14/20
  • 52 Week Low20.58
  • 52 Week Low Date08/12/21
  • Market Cap3.607B
  • Shares Out142.18M
  • 10 Day Average Volume0.74M
  • Dividend-
  • Dividend Yield-
  • Beta1.08
  • YTD % Change1.66

RATIOS/PROFITABILITY

  • EPS (TTM)-1.82
  • P/E (TTM)-13.90
  • Fwd P/E (NTM)-10.71
  • EBITDA (MRQ)-234.096M
  • ROE (MRQ)-21.83%
  • Revenue (MRQ)38.39M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-621.84%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/02/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Allogene Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer...
Arie Belldegrun M.D.
Chairman
David Chang M.D. Ph.D.
President
Eric Schmidt Ph.D.
Chief Financial Officer
Alison Moore Ph.D.
Chief Technology Officer
Rafael Amado M.D.
Executive Vice President
Address
210 E Grand Ave
South San Francisco, CA
94080-4811
United States

Top Peers

SYMBOLLASTCHG%CHG
TPTX
Turning Point Therapeutics Inc
72.68-1.79-2.40%
SWTX
SpringWorks Therapeutics Inc
68.74+0.04+0.06%
ARNA
Arena Pharmaceuticals Inc
59.78-0.30-0.50%
PRNB
PRTA
Prothena Corporation PLC
75.62+0.30+0.40%